RCUS — Arcus Biosciences Income Statement
0.000.00%
Last trade - 00:00- $2.71bn
- $1.83bn
- $247.00m
Annual income statement for Arcus Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 383 | 112 | 117 | 258 | 247 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 329 | 392 | 457 | 588 | 633 |
| Operating Profit | 54.2 | -280 | -340 | -330 | -386 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 54.6 | -266 | -301 | -282 | -353 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 52.8 | -267 | -307 | -283 | -353 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 52.8 | -267 | -307 | -283 | -353 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 52.8 | -267 | -307 | -283 | -353 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.714 | -3.71 | -4.15 | -3 | -3.29 |